Burmeister v. Peterson

CourtDistrict Court, N.D. California
DecidedFebruary 8, 2024
Docket3:22-cv-03178
StatusUnknown

This text of Burmeister v. Peterson (Burmeister v. Peterson) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Burmeister v. Peterson, (N.D. Cal. 2024).

Opinion

1 2 3 4 UNITED STATES DISTRICT COURT 5 NORTHERN DISTRICT OF CALIFORNIA 6 7 JEANNETTE BURMEISTER., Case No. 22-cv-03178-AMO

8 Plaintiff, ORDER GRANTING MOTION TO 9 v. DISMISS

10 DANIEL PETERSON, et al., Re: Dkt. No. 55 Defendants. 11

12 13 Before the Court is Defendants Dr. Daniel Peterson and Sierra Internal Medicines’ 14 (collectively, the “Peterson Defendants”) motion to dismiss for lack of personal jurisdiction. 15 Having read the parties’ papers and carefully considered their arguments and the relevant legal 16 authority, the Court hereby GRANTS the motion to dismiss, for the following reasons. 17 I. BACKGROUND 18 A. Factual Background 19 Plaintiff Jeannette Burmeister’s (“Burmeister”) allegations stem from a decade-long 20 doctor-patient relationship with Dr. Daniel Peterson (“Dr. Peterson”), who treated Burmeister for 21 Myalgic Encephalomyelitis (“ME”) through an Ampligen study at Sierra Internal Medicine, his 22 Nevada medical office. “Compl.” (ECF 1-1) ¶¶ 38-42, 74-75.1 Burmeister generally alleges that 23 Defendants failed to fulfill or refund Burmeister’s one-year supply of Ampligen, which she 24 purchased from Defendants for $41,600, and that Defendants improperly removed her from the 25

26 1 Because the Court is considering a motion to dismiss pursuant to Rule 12(b)(2), it accepts the factual allegations in Plaintiff’s complaint as true. See Schwarzenegger v. Fred Martin Motor Co., 27 374 F.3d 797, 800 (9th Cir. 2004) (the court must take uncontroverted allegations in the complaint 1 Ampligen clinical trial. Id. ¶¶ 79-133; MTD at 8-9. 2 Dr. Peterson lives and works in Nevada. Compl. ¶ 5. He is the president, secretary, 3 treasurer, director, and sole shareholder of Sierra, a Nevada corporation. Id. ¶ 6. Simmaron is a 4 Nevada nonprofit founded by Dr. Peterson and does not join this motion as it has conceded 5 personal jurisdiction. Id. ¶ 7; ECF 31 ¶ 18. Dr. Peterson maintains a Nevada and a California 6 medical license, but his practice has been entirely in Nevada since the late 1990s. “Peterson 7 Decl.” (ECF 55-1) ¶ 5. The Peterson Defendants do not have property or bank accounts in 8 California and do not pay California taxes. Id. ¶¶ 6-7. 9 In 2011, Burmeister’s husband, Ed Burmeister, attended a presentation given by Dr. 10 Peterson in Cupertino, California, on ME diagnosis and research. “Ed Burmeister Decl.” (ECF 11 58-2) ¶ 6. One slide of the presentation referenced the need for “cooperative patients,” which Mr. 12 Burmeister understood to constitute “outreach” to potential patients. Id. ¶ 6. Mr. Burmeister 13 approached Dr. Peterson about the possibility of Ms. Burmeister seeing him for treatment, and Dr. 14 Peterson “indicated that [Ms. Burmeister] could contact him.” Id. ¶ 7. Ms. Burmeister admits that 15 she was already familiar with Dr. Peterson’s expertise and had “made some preliminary efforts” to 16 obtain a consultation with him. “Burmeister Decl.” (ECF 58-1) ¶ 10. She “reached out to Dr. 17 Peterson” by letter, asking for a work-up and consultation and sending patient information. Id. ¶ 18 11. Dr. Peterson offered her an appointment at Sierra in Incline Village, Nevada, which she 19 attended on January 3, 2012. Id. 20 After Burmeister attended the initial appointment at Sierra, she joined Dr. Peterson’s 21 Ampligen trial, and he treated her at his Nevada practice for nine years. Id.; Compl. ¶¶ 40-42, 74- 22 75, 147. Due to the experimental nature of Ampligen, Burmeister was responsible for purchasing 23 her own supply of the drug, which Sierra stored and administered. Id. ¶¶ 43-44. Supplemental to 24 this treatment, Dr. Peterson prescribed Intravenous Immunoglobin (“IVIG”) infusions for 25 Burmeister, which she initially received in the Nevada medical clinic. Id. ¶ 45; Burmeister Decl. 26 ¶¶ 17-18. Beginning in 2015, Dr. Peterson provided the IVIG prescription to a home infusion 27 company selected by Burmeister and she started receiving infusions at her home in California. 1 companies administered the IVIG infusions for the next five years and provided visit summaries to 2 Dr. Peterson. Burmeister Decl. ¶¶ 17-18. Because Dr. Peterson has a California medical license, 3 his patients did not need a California doctor to review prescriptions the patients filled in 4 California. Peterson Decl. ¶ 18. 5 On March 13, 2017, Burmeister agreed to purchase a one-year supply of Ampligen from 6 Dr. Peterson for $41,600, which would be stored at Defendants’ office. Compl. ¶¶ 56-59. Shortly 7 after, Defendants suspended Burmeister’s treatment, preventing her from accessing the Ampligen. 8 Id. ¶ 61. Defendants claimed that Burmeister had only been charged for the medicine she used 9 and that the Peterson Defendants only purchased a four-week supply of Ampligen. Id. ¶ 62. In 10 February 2018, the Ampligen treatment resumed until March 2022, when Defendants ejected 11 Burmeister from the clinical study. Id. ¶¶ 68, 75. Burmeister’s claims generally arise from the 12 Peterson Defendants’ failure to provide her with, or refund her for, the Ampligen, and subsequent 13 ejection of her from the clinical study. See id. ¶¶ 79-133. 14 B. Procedural Background 15 On April 28, 2022, Burmeister filed a complaint in San Mateo Superior Court alleging 16 seven causes of action against Defendants Dr. Daniel Peterson, Sierra Internal Medicine 17 (“Sierra”), and Simmaron Research (“Simmaron”) (collectively, “Defendants”). Burmeister 18 alleges that Sierra and Simmaron are Dr. Peterson’s alter egos. Compl. ¶ 11. Burmeister alleges 19 (1) fraud; (2) breach of contract; (3) conversion; (4) civil penalties for receipt of stolen property; 20 (5) restitution or unjust enrichment; (6) intentional infliction of emotional distress; and (7) 21 violations of California Health and Safety Code Section 123120. Id. at 7. Defendants removed 22 the action to this Court on May 31, 2022. ECF 1. 23 On October 31, 2022, the Peterson Defendants filed the first motion to dismiss for lack of 24 personal jurisdiction. ECF 33. The Court denied the motion to dismiss without prejudice, finding 25 that there were “too many unknowns to determine that there is no jurisdiction.” ECF 45. The 26 Court authorized the parties to take jurisdictional discovery over a 90-day period and reminded 27 Burmeister that it is “conduct by a defendant – not facts about a plaintiff – that creates personal 1 jurisdictional discovery. On May 10, 2023, the Peterson Defendants filed a renewed motion to 2 dismiss for lack of personal jurisdiction, the motion considered by this order. “MTD” (ECF 55).2 3 The parties agree that there is no general jurisdiction. “Response” (ECF 58) at 20 n.7; “Reply” 4 (ECF 59) at 4. Instead, they contest whether there is specific jurisdiction over the Peterson 5 Defendants. See Response at 20-30. 6 II. LEGAL STANDARD 7 Under Federal Rule of Civil Procedure 12(b)(2), a defendant may move to dismiss a claim 8 for lack of personal jurisdiction. “When a defendant moves to dismiss for lack of personal 9 jurisdiction, the plaintiff bears the burden of demonstrating that the court has jurisdiction over the 10 defendant.” Pebble Beach Co. v. Caddy, 453 F.3d 1151, 1154 (9th Cir. 2006); see also 11 Schwarzenegger v. Fred Martin Motor Co., 374 F.3d 797, 800 (9th Cir. 2004) (same). “The 12 general rule is that personal jurisdiction over a defendant is proper if it is permitted by a long-arm 13 statute and if the exercise of that jurisdiction does not violate federal due process.” Pebble Beach, 14 453 F.3d at 1154.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Burger King Corp. v. Rudzewicz
471 U.S. 462 (Supreme Court, 1985)
Mina Wright v. James Yackley
459 F.2d 287 (Ninth Circuit, 1972)
Sher v. Johnson
911 F.2d 1357 (Ninth Circuit, 1990)
Leadsinger, Inc. v. BMG Music Publishing
512 F.3d 522 (Ninth Circuit, 2008)
Jones v. Williams
660 F. Supp. 2d 1145 (N.D. California, 2009)
Truck Insurance Exchange v. Fireman's Fund Insurance
6 Cal. App. 4th 1050 (California Court of Appeal, 1992)
Daimler AG v. Bauman
134 S. Ct. 746 (Supreme Court, 2014)
George Williams v. Yamaha Motor Corp. USA
851 F.3d 1015 (Ninth Circuit, 2017)
K. Morrill v. Scott Financial Corp.
873 F.3d 1136 (Ninth Circuit, 2017)
Ford Motor Co. v. Montana Eighth Judicial Dist.
592 U.S. 351 (Supreme Court, 2021)
Schwarzenegger v. Fred Martin Motor Co.
374 F.3d 797 (Ninth Circuit, 2004)
Matt Yamashita v. Lg Chem, Ltd.
62 F.4th 496 (Ninth Circuit, 2023)

Cite This Page — Counsel Stack

Bluebook (online)
Burmeister v. Peterson, Counsel Stack Legal Research, https://law.counselstack.com/opinion/burmeister-v-peterson-cand-2024.